Press Release
<< Back
Verastem to Host Analyst and Investor Day on May 2, 2018
The agenda will include an in-depth discussion of the Company’s lead oral oncology candidate, duvelisib, including the unmet need of patients, where phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma inhibitors fit into the treatment paradigm and the opportunity for duvelisib in the growing chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL) population and beyond.
The program will also feature key opinion leaders in the hematologic oncology field, including:
-
Jennifer Brown , MD, PhD
Associate Professor of Medicine,Harvard Medical School Director, and Director, CLL Center of theDivision of Hematologic Malignancies ,Dana-Farber Cancer Institute -
Ian Flinn , MD, PhD
Director, Blood Cancer Research Program atSarah Cannon Research Institute , and Lead Investigator of the DUO and DYNAMO Studies -
Steven Horwitz , MD
Medical Oncologist,Memorial Sloan Kettering Cancer Center and NYC Health + Hospitals/Bellevue -
Brian Koffman , MDCM, DCFP, FCFP, DABFP, MSEd
Physician, Medical Director of theChronic Lymphocytic Leukemia (CLL) Society and CLL Patient -
Lori Kunkel , MD
Oncology Drug Development Expert and Biotech Advisor, Member of the Board of Directors atTocagen Inc. , Former Chief Medical Officer, Pharmacyclics
Kindly reach out to
A live and archived webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at www.verastem.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.
About
For more information, please visit www.verastem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180423005198/en/
Source:
Verastem, Inc.
Marianne M. Lambertson, 781-292-4273
Vice
President, Corporate Communications
Investor Relations/Public
Relations
mlambertson@verastem.com